Skin SSG (Anglia East & Anglia West)
|
|
- Daniela Booker
- 5 years ago
- Views:
Transcription
1 Skin SSG (Anglia East & Anglia West) Author: Dr Jennifer Garioch, Consultant Dermatologist Dr Pamela Todd, Consultant Dermatologist Approved by: Anglia Cancer Network Skin NSSG Approved on: Reviewed and re-issued with no changes 11 th May 2011 Next review due: May 2013 Ref: AngCN-SSG-S3 Version 6.0
2 CONTENTS Introduction... 3 General Considerations... 3 Pathologists... 3 Melanoma... 3 Sampling of specimens... 3 Pathological reporting of Melanoma... 3 Squamous Cell Carcinoma... 4 Sampling of Lesions... 4 Pathological Reporting of Squamous Cell Carcinoma... 4 Basal Cell Carcinoma... 4 Pathological Reporting of Basal Cell Carcinoma... 4 Cutaneous T Cell Lymphoma (CTCL)... 5 Skin Biopsies for CTCL... 5 Pathological Reporting of CTCL... 5 AngCN Skin Cancer SMDT (East and West) Meetings:... 6 Pathological Aspects... 6 Skin Cancer SMDT (East)... 6 Skin Cancers... 6 Melanoma:... 6 Squamous cell carcinoma:...6 Basal cell carcinoma:... 7 Other cases:... 7 Skin lymphoma SMDT (East) meeting organisation... 7 Skin Cancer SMDT (West)... 8 Malignant Melanoma... 8 Squamous Cell Carcinoma... 9 Basal cell carcinomas Skin lymphoma SMDT (West) meeting organisation Referral to Addenbrooke s for SMDT review Evidence of Agreement Monitoring the Effectiveness of the Process Page 2 of 13
3 Introduction Systematic, standardised and accurate specimen preparation, histopathology examination and reporting are essential steps in the management of patients with skin cancer. High quality histopathology is critical in determining the diagnosis, prognosis and optimal therapy for skin cancers. Pathology databases are central to the ensuring that all new skin cancer cases can be identified and submitted for discussion to the relevant MDTs. General Considerations: Pathologists, Specimen Preparation, Sampling and Reporting Pathologists Pathologists examining skin cancers should be core members of the MDT and should participate in a general or skin EQA. Melanoma Sampling of specimens Excised tumours should be sampled in their entirety, unless very large, when sampling is at the pathologist s discretion Pathological reporting of Melanoma Pathological reports should contain the following minimum data set: Site Surgical procedure for example excision or re-excision, punch, or shave biopsy Macrosopic description including dimensions of the specimen Comment as to whether this is a primary lesion, a local recurrence or a metastatic lesion. Ulceration whether present or absent and its extent Breslow depth to the nearest 0.1mm The growth phase should be recorded i.e. whether purely radial growth phase or whether there is any evidence of vertical growth phase Mitotic rate per sq mm Presence of lymphovascular invasion Presence of perineural involvement Presence or absence of regression Histological type Completeness of excision and peripheral and deep margins recorded in mm Pathological staging Tumour infiltrating lymphocytes Page 3 of 13
4 Pre-existing naevus Squamous Cell Carcinoma Sampling of Lesions Excised lesions should be adequately sampled. Pathological Reporting of Squamous Cell Carcinoma Pathological reports should contain the following minimum data: Site Surgical procedure for example excision or re-excision, currettage punch, or shave biopsy Macrosopic description including dimensions of the specimen Thickness of lesion in mm, excluding surface layers of keratin. Degree of differentiation (Broder s grades if preferred) Presence of lymphovascular invasion Presence of perineural involvement Histological subtype if relevant for example whether desmoplastic, acantholytic, spindle cell or verrucous Clearance of peripheral and deep margins measured Basal Cell Carcinoma Pathological Reporting of Basal Cell Carcinoma Pathological reports should contain the following minimum data: Site Surgical procedure for example excision or re-excision, curettage, punch, or shave biopsy Macrosopic description including dimensions of the specimen Perineural involvement, if present Metatypical/basisquamous differentiation, if present Histological subtype for example whether nodular, superficial, infiltrative, micronodular etc Clearance of peripheral and deep margins measured Breslow depth to be reported on incisional/punch biopsies in order to determine feasibility of photodynamic therapy. Page 4 of 13
5 Cutaneous T Cell Lymphoma (CTCL) Skin Biopsies for CTCL Repeat skin biopsies from lesional skin are often required to confirm a diagnosis of CTCL Histology, immunophenotypic and preferably TCR gene analysis should be performed on all tissue samples. Fresh tissue should ideally be available for molecular studies, Pathological Reporting of CTCL The following should be noted; The presence or absence of epidermotropism Depth of the infiltrate Morphology or cytology of atypical cells and the presence of large cell transformation Folliculotropism, syringotropism, granuloma formation, angiocentricity and subcutaneous infiltration Immunophenotype markers should be performed on paraffin embedded tissue and include T cell markers (CD2 CD3 CD4 CD8) B Cell markers (CD20) and the activation marker CD30. Additional markers such as p53 may have prognostic significance in mycosis fungoides. In CTCL variants, markers of cytotoxic function such as TIA-1, the monocyte/macrophage marker CD68 and the NK cell marker CD56 may be useful. Ideally all the pathology should be reviewed by a central panel (usually within cancer centres0 The histology (after correlation with the clinical feature should be classified according to an integration of the WHO and EORTC classification (Grade A/level 3) Page 5 of 13
6 AngCN Skin Cancer SMDT (East and West) Meetings: Pathological Aspects Skin Cancer SMDT (East) The skin cancer SMDT for the eastern part of the network is based at the Norfolk and Norwich University Hospital Skin Cancers Monday (weekly), starting at 8:00 Pathology core MDT members: Drs Tim Barker, Urszula Carr, Joe Murphy, Pathology extended MDT members: Drs Laszlo Igali, Jamie Sington and Geoff Waters. Cases discussed: Melanoma: The following cases are included in the MDT meeting: new melanoma, metastatic and recurrent melanoma positive sentinel lymph node biopsies positive lymph nodes following lymph node clearance dysplastic naevi if there is a concern about the possibility of melanoma melanomas excised or biopsied in primary care All melanomas with a Breslow thickness of 0.75mm and greater are discussed at the MDT. Selected cases with histopathological points of interest or difficulty are also discussed. Melanomas with a Breslow thickness of less than 0.75mm which have been adequately excised and with no further clinical, histological or management issues are noted but not discussed. Squamous cell carcinoma: The following cases are discussed at the MDT meeting: tumours 6mm thick or more pt2 or above incompletely or narrowly excised tumours (<1mm margins) perineural or vascular invasion poorly differentiated tumours recurrent or metastatic tumours tumours from special or high risk sites (ear, lip, perineum, eyelid/canthus, sole of foot) Page 6 of 13
7 specific histological subtypes (clear cell, desmoplastic, verrucous, carcinosarcoma, and adenosquamous) those associated with immunosuppression including transplant tumours associated with burns, albinism, xeroderma, post-irradiation squamous cell carcinomas excised or biopsied in primary care All other cases are listed but not discussed unless there is a particular issue. Basal cell carcinoma: basal cell carcinomas incompletely or narrowly excised (< 1mm margin) tumours with perineural invasion tumours for consideration of Mohs surgery basal cell carcinomas (except superficial BCCs) excised in primary care Other cases: The following cases are also discussed at the MDT meeting: sarcoma atypical fibroxanthoma, dermatofibrosarcoma protuberans, leiomyosarcoma, sarcomas superficial to the deep fascia, sarcomas biopsied or excised in primary care rare skin tumours as listed in the NICE IOG guidance The list of patients to be discussed is generated by searching the NNUHFT histopathology database. Cases from other Trusts James Paget, Queen Elizabeth Hospital and Ipswich - are submitted by faxing or ing the MDT proforma. Other cases to be discussed can be added by ing or phoning Lorraine Nelhams, the MDT co-ordinator for NNUHFT or Rachel Stevenson, the Patient Pathway Co-ordinator for NNUHFT. Cases to be added - via proforma - by to Lorraine Nelhams (coordinator), by midday preceding Thursday. Cases collected and reviewed by pathologist, all cases discussed at the MDT. Decisions and discussion recorded onto the proforma during the meeting, further investigations are initiated, completed and the relevant information recorded on the subsequent meeting. If necessary, supplementary report issued. Pathology processing and reporting: According to the RCPath Standards and Minimum Datasets. The pathology report contains the necessary elements according to the above document, in case of the malignant melanoma, in a form of a template-based report. Skin lymphoma SMDT (East) meeting organisation Page 7 of 13
8 The skin lymphoma MDT for the eastern part of the network is based at the Norfolk and Norwich University Hospital and is held bimonthly on Wednesdays at Pathology lead - Dr James Sington Other core skin lymphoma MDT pathology members: Drs Laszlo Igali and Tim Barker Cases discussed: all skin lymphoproliferative diseases, suggested for discussion by the pathologists and dermatologists. Cases to be added - by midday preceding Thursday. Cases collected and reviewed by pathologist, all cases discussed at the MDT. Pathology processing and reporting: According to the RCPath Standards and Minimum Datasets. General comments: Skin malignancies reported by all pathologists, difficult/unusual cases are referred to a core team of pathologist with special interest in dermatopathology. This core team includes: Dr T Barker, Dr J Murphy, Dr G Waters, Dr J Sington, Dr Urszula Carr and Dr L Igali. The malignant melanocytic lesions are double reported at the discretion of the reporting pathologists. Skin cancer cases requiring a further opinion are sent to individual national experts. Skin Cancer SMDT (West) The SMDT (West) is based at Cambridge University Hospital Trust (Addenbrooke s). The West Suffolk Hospital, Peterborough District Hospital, Bedford Hospital and Hinchingbrooke Hospital participate in the SMDT via a video teleconferencing link Pathology leads Dr Ed Rytina, Dr Vicky Bardsley and Dr Rebecca Brais (core members) Weekly (Monday) at 11-15am The cases discussed fall into 4 main groups, namely Melanomas, squamous cell carcinomas, basal cell carcinomas and cutaneous lymphomas. Malignant Melanoma Pathological Case Identification List of patients from Addenbrooke s generated by the histopathology department (Anne Coghill) on the Wednesday before the meeting using Meditech search: PMEL (searches the SNOMED diagnosis field for melanoma, lentigo maligna, Hutchinson s, Spitz, spitzoid and dysplastic naevus ). Page 8 of 13
9 Meditech generated list reviewed and revised by pathologist. Included in the meeting are all new melanoma metastatic melanoma,, lymph node biopsies, FNAs and excisions, dysplastic naevi where there was clinical concern about melanoma. Exclusions dysplastic naevi in which there was no clinical concern about melanoma. Lesions with a benign clinical diagnosis and a benign histological diagnosis are not reviewed. Revised list sent to MDT coordinator (Claire Herbert). A comprehensive list of all patients to be discussed is then compiled by the MDT coordinator and circulated to SMDT members Additions by pathologists, clinicians or melanoma nurse specialist by or phone to MDT coordinator. Selected relevant slides from all cases reviewed by pathologist by rapid review only, with rapid assessment of histological parameters. The cases discussed in detail at the MDT meeting are according to Skin SSG guidelines for the melanoma MDT, which includes all cases of stage 2b and above selected cases with histopathological points of interest or difficulty. Excised melanomas which have been managed according to the ACN guidelines with no further clinical, histological or management issues are noted but not discussed in detail, providing there is adequate documentation that management has been completely in accordance with ACN guidelines Decisions and discussions recorded on a JCIS proforma by the lead clinician at the meeting which is subsequently sent to the relevant clinician responsible for the care of the patient and the general practitioner. Squamous Cell Carcinoma Pathological Case Identification A list of patients from Addenbrooke s generated by the histopathology department (Anne Coghill) on the Wednesday before the meeting using Meditech search: PSCC (searches the SNOMED diagnosis field for Squamous cell carcinoma Meditech generated list reviewed and revised by the pathologist. Included in the meeting are all invasive SCCs. Those for histological review (as agreed by the Skin SSG) are: incision/punch biopsies, Page 9 of 13
10 tumours over 6mm depth, Clark s level 5, pt2 or above, incompletely excised or close (under 1mm) margins, poorly differentiated, vascular or perineural invasion, recurrent tumours metastases, tumours from special or high risk sites (ear, lip, perineum, eyelid/canthus, sole of foot), specific histological subtypes (clear cell, desmoplastic, verrucous, carcinoma, adenosquamous) those associated with immunosuppression (including transplant), xeroderma, albinism, burns, LS et A, post-irradiation or other pre-existing dermatoses. All other cases (i.e. thin, fully excised tumours) are listed but not discussed (unless there is a particular clinical issue); the histology is NOT reviewed before the meeting. In situ disease is not included in the meeting. Decisions and discussions recorded on a JCIS proforma by the lead clinician at the meeting which is subsequently sent to the relevant clinician responsible for the care of the patient. Post MDT investigations initiated and any additional information or alterations in diagnosis included in an addendum to the original report. Basal cell carcinomas Weekly Monday 11-15am Pathology lead - Dr Ed Rytina Pathological Case identification List of patients from Addenbrooke s generated by the histopathology department (Anne Coghill) on the Wednesday before the meeting using Meditech search: A list of all Basal cell carcinomas is obtained and noted by the MDT. The cases discussed are as follows: Basal cell carcinomas with involved or close margins. Basal cell carcinomas requiring Mohs microsurgery Revised lists in which patients to be noted and those to be discussed are highlighted and sent to MDT coordinator (Claire Herbert). Additions by pathologists or clinicians by or phone to MDT Coordinator. Selected relevant slides from all cases reviewed by pathologist by rapid review only, with rapid assessment of histological parameters. Page 10 of 13
11 The cases discussed at the MDT meeting are according to Skin SSG guidelines for the BCC MDT, which includes selected cases with histopathological points of interest or difficulty. Adequately excised tumours with no further clinical, histological or management issues are noted but not discussed. Decisions and discussions recorded by the lead clinician at the meeting. Post MDT investigations initiated and any additional information or alterations in diagnosis included in an addendum to the original report. Skin lymphoma SMDT (West) meeting organisation The skin lymphoma MDT for the western part of the network is based at Addenbrooke s Hospital. Skin lymphoma cases are discussed in: Weekly Skin cancer SMDT (11-15 Monday am) when urgent assessment of cases and urgent management plans are required. Three times yearly SMDT where the cases are discussed in greater depth and the patients also attend for clinical assessment. (Usually 2-30 pm the 3rd Wednesday afternoon of the month) Pathology lead - Dr Rebecca Brais Other core skin lymphoma MDT pathology members: Drs Ed Rytina, Dr Vicky Bardsley Cases discussed: all skin lymphoproliferative diseases, referred for discussion by pathologist, clinical oncologists and dermatologists. Cases to be added - by midday preceding Thursday. Cases collected and reviewed by pathologist, all cases discussed at the MDT. Pathology processing and reporting: According to the RCPath Standards and Minimum Datasets. Referral to Addenbrooke s for SMDT review Cases from other trusts (WSH, PDH, Hinchingbrooke and Bedford) to be discussed fortnightly at the SMDT are submitted by faxed or ed by proforma by the preceding Thursday (mid-day). Standard cases are not sent for routine central histology review but where histopathology review is required, the slides and blocks are sent for review to Dr Rytina, Dr Bardsley or Dr Brais Cases can be referred for histopathological specialist review by local Pathologists if required, either for diagnosis before the SMDT, or after discussion at the SMDT following a decision for referral by the MDT. Request for specialist review can be made to the local pathologist by the patient s clinician. Pathology Referral pathways: Page 11 of 13
12 Skin malignancies reported by all pathologists, difficult/unusual cases are referred to a core team of pathologist with special interest in dermatopathology. This core team includes: Dr Ed Rytina, Dr Vicky Bardsley and Dr Rebecca Brais. The malignant melanocytic lesions are double reported at the discretion of the reporting pathologists Skin cancer cases necessary for secondary and tertiary referral to Addenbrooke s, St John s Institute of Dermatopathology or individual national experts. Page 12 of 13
13 Evidence of Agreement This Guideline has been agreed by: The Anglia Cancer Network Board Name: Carole Taylor-Brown Position: Chief Executive Suffolk PCT and Chair of the Anglia Cancer Network Board Date agreed: 9 th June 2010 The SSG Members This document was agreed to at the Joint Skin SSG Meeting on 12 th May Monitoring the Effectiveness of the Process a) Process for Monitoring compliance and Effectiveness - Review of compliance as determined by audit. Any non compliance to be presented by QA Manager to the AngCN Business Meeting on an annual basis the minutes of this meeting are retained for a minimum of five years. b) Standards/Key Performance Indicators This process forms part of a quality system working to, but not accredited to, International Standard BS EN ISO 9001:2008. The effectiveness of the process will be monitored in accordance with the methods given in the quality manual, AngCN-QM Equality and Diversity Statement This document complies with the Suffolk PCT Equality and Diversity statement an EqIA assessment is available on request to Anglia Cancer Network QA Manager, Gibson Centre, Exning Road, Newmarket, CB8 7JG. Disclaimer It is your responsibility to check against the electronic library that this printed out copy is the most recent issue of this document. Please notify any changes required to the Anglia Cancer Network Quality Assurance Manager Page 13 of 13
Skin SSG (Anglia East & Anglia West)
Guidelines for Referrals between Skin LMDT and SMDT Skin SSG (Anglia East & Anglia West) Author: Dr Jennifer Garioch, Consultant Dermatologist Dr Pamela Todd, Consultant Dermatologist Approved by: Anglia
More informationBrain and CNS tumours Presentation pathway
Brain and CNS tumours Presentation pathway Ref: AngCN-SSG-BC16 Page 1 of 8 1 Background and Scope This presentation pathway deals with the pathway of referral from all aspects of primary care to hospitals
More information1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.
Skin Cancer follow up guidelines If NEW serious diagnosis given: 1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. 2. Free prescription information details. 3.
More informationSkin SSG (Anglia East & Anglia West)
Guidelines for the Management of Skin Cancer in Specific Anatomical Sites Skin SSG (Anglia East & Anglia West) Author: Dr Jennifer Garioch, Consultant Dermatologist Dr Pamela Todd, Consultant Dermatologist
More informationChemotherapy Training and Assessment Policy. For Medical Prescribers and Pharmacy Verifiers
Chemotherapy Training and Assessment Policy For Medical Prescribers and Pharmacy Verifiers For approvals and version control see Document Management Record on page 6 Doc Ref: AngCN-CCG-C36 Approved and
More informationRef No: AngCN-SSG-Sa9. H:\Cancer Network\Tumour Site\Sarcoma\Peer Review\Active\AngCN-SSG- Sa9_v2_Anglia_Configuration_Sarcoma_Services.
Anglia Cancer Network Configuration of Sarcoma Services Please note this document has only been partially approved. For further details, approvals and version control please see Document Management Record
More informationDavid B. Troxel, MD. Common Medicolegal Situations: Misdiagnosis of Melanoma
Common Medicolegal Situations: Misdiagnosis of Melanoma David B. Troxel, MD Medical Director, The Doctors Company, Napa, California Clinical Professor Emeritus, University of California at Berkeley Past
More informationGuidance for the Network Review of Chemotherapy Errors
Guidance for the Network Review of Chemotherapy Errors For approvals and version control see Document Management Record on page 8 Doc Ref: AngCN-CCG-C31 Approved and published: March 2013 Page 1 of 8 Table
More informationPrimary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type
Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female
More informationIdentifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018
Identifying Skin Cancer Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 American Cancer Society web site Skin Cancer Melanoma Non-Melanoma
More informationGUIDELINES FOR THE MANAGEMENT OF BLADDER CANCER
GUIDELINES FOR THE MANAGEMENT OF BLADDER CANCER For approvals and version control see Document Management Record on page 9 Ref: AngCN-SSG-U4 Page 1 of 11 Approved and Published: Aug 2012 TABLE OF CONTENTS
More informationMelanoma. Consultation on draft guideline - stakeholder comments. Comments to be submitted before 5pm on Friday 13 March 2015
Please note: Please fill in both the stakeholder organisation and name of commentator fields. We cannot accept forms with attachments such as research articles, letters or leaflets. Stakeholder organisation(s)
More informationProposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL
Proposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL on behalf of Dr Louise Lansbury, Prof Fiona Bath-Hextall Nottingham Centre for Evidence Based
More informationDepartment of Dermatology, Queen Margaret & Victoria Hospitals
Department of Dermatology, Queen Margaret & Victoria Hospitals Management of primary skin cancer A copy of these local guidelines, national guidelines, information leaflets and other useful information
More informationGUIDELINES FOR THE MANAGEMENT OF
GUIDELINES FOR THE MANAGEMENT OF RENAL CANCER Date of endorsement: July 2011 Authors: Mr. RD Mills & Mr. WH Turner Ref: AngCN-SSG-U3 Page 1 of 14 Approved and Published: Aug 2011 Title: Guidelines for
More informationProtocol applies to melanoma of cutaneous surfaces only.
Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC
More informationSomerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Skin Cancer Network Site Specific Group. Clinical Guidelines.
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services Skin Cancer Network Site Specific Group June 2017 Revision due: April 2019 Page 1 of 70 VERSION CONTROL THIS IS A CONTROLLED DOCUMENT.
More informationMalignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha
Malignant tumors of melanocytes : Part 3 Deba P Sarma, MD., Omaha Let s go over one case of melanoma using the following worksheet. Of the various essential information that needs to be included in the
More informationMalignant Melanoma Care Pathway
Malignant Melanoma Care Pathway Level 1-4 Community Skin Cancer Service Sussex Community Dermatology Service Version 3.0 Scope of Community Services for Malignant Melanoma All suspected cases of malignant
More informationAnnual Report Skin MDT
Annual Report Skin MDT University Hospitals Bristol NHS Foundation Trust 0117 923 0000 Minicom 0117 934 9869 www.uhbristol.nhs.uk Agreement and Approval Skin MDT Lead Clinician David DeBerker Date 29/08/2012
More informationDermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.
Squamous cell carcinoma (SCC): A common malignant tumor of keratinocytes arising in the epidermis, usually from a precancerous condition: 1- UV induced actinic keratosis, usually of low grade malignancy.
More informationA PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL
A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL OBJECTIVES Discuss current trends and changing concepts in our understanding of
More informationWHAT DOES THE PATHOLOGY REPORT MEAN?
Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also
More informationDesmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC
R/O BCC Sabine Kohler, M.D. Professor of Pathology and Dermatology Dermatopathology Service Stanford University School of Medicine Clinical Information 74 y.o. man with lesion on left side of neck r/o
More informationPATHOLOGY OF THE SKIN 2. Tumours of the skin
PATHOLOGY OF THE SKIN 2. Tumours of the skin Máirín E. McMenamin MB MRCPI FRCPath Dip (Dermatopathol) RCPath St. James s Hospital and University of Dublin, Trinity College Tumour (Neoplasia) Benign or
More informationVULVAR CARCINOMA. Page 1 of 5
VULVAR CARCINOMA EXAMPLE OF A VULVAR CARCINOMA USING PROPOSED TEMPLATE Case: Invasive squamous cell carcinoma arising in D-VIN Tumor in left labia major Left partial vaginectomy and sentinel lymph node
More informationMelanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG
Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG At tumor board, a surgeon insists that all level II melanomas are invasive since they have broken through the
More informationCancer Reporting for Dermatologists. Florida Department of Health Florida Cancer Data System. March 9, Agenda
Cancer Reporting for Dermatologists Florida Department of Health Florida Cancer Data System March 9, 2011 Agenda Welcome Introductions Cancer Reporting in Florida BETA Participation Expectations Review
More informationGuideline for the Diagnosis of Breast Cancer
Guideline for the Diagnosis of Breast Cancer Version History Version Date Brief Summary of Change Issued 2.0 May 2007 Approved by the Governance Committee 2.0 25.11.08 Discussed at the NSSG 2.1 5.12.08
More informationShared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs. Gynaecological sarcomas Version 1
Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Gynaecological sarcomas Version 1 Background This guidance is to provide direction for the management of patients with sarcomas
More informationSkin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012
Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012 Case Presentation 57 yo man with 3 month hx of a nonhealing < 1 cm right
More informationCutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.
Cutaneous Malignancies: A Primer Marissa Heller, M.D. Associate Director of Dermatologic Surgery Department of Dermatology Beth Israel Deaconess Medical Center December 10, 2016 Skin Cancer Non-melanoma
More informationContrast with Australian Guidelines A/Pr Pascale Guitera,
Contrast with Australian Guidelines A/Pr Pascale Guitera, Dermatologist, Sydney University NO CONFLICT OF INTEREST Sydney Melanoma Diagnostic Centre, RPAH 2011 2008 225 pages 16 pages http://www.cancer.org.au/file/healthprofessionals/clinica
More informationSquamous Cell Carcinoma. Basal Cell Carcinoma. Regional Follow-up Guidelines
West of Scotland Cancer Network Skin Cancer Managed Clinical Network Squamous Cell Carcinoma Basal Cell Carcinoma Regional Follow-up Guidelines Prepared by Dr M Porter, Dr A Matthews Approved by Skin Cancer
More informationWest Midlands Sarcoma Advisory Group
West Midlands Sarcoma Advisory Group Guideline for the Initial Investigation and Referral to Sarcoma Specialist Multi Disciplinary Team for Suspected Sarcoma of Soft Tissue Extremities (limbs and trunk
More informationSKIN CANCER. Most common cancer diagnosis 40% of all cancers
SKIN CANCER Most common cancer diagnosis 40% of all cancers OBJECTIVES Review common and uncommon cancers of the skin. Special emphasis on melanoma and dysplastic nevus Review pathology/tnm/staging, which
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationKnow who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated
Lindy P. Fox, MD Assistant Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco Applies to adults without history of malignancy or premalignant
More information12. Malignant Melanoma of Skin
KEY FACTS 12. Malignant Melanoma of Skin ICD-9 172 On average 160 melanomas of the skin were registered per year. Twice as common in females than in males. Higher than expected numbers in Southern Board
More informationEpithelial Cancer- NMSC & Melanoma
Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug
More informationBasal cell carcinoma 5/28/2011
Goal of this Presentation A practical approach to the diagnosis of cutaneous carcinomas and their mimics Thaddeus Mully, MD University of California San Francisco To review common non-melanoma skin cancers
More informationActivity Report March 2013 February 2014
West of Scotland Cancer Network Skin Cancer Managed Clinical Network Activity Report March 2013 February 2014 Dr Girish Gupta Consultant Dermatologist MCN Clinical Lead Tom Kane MCN Manager West of Scotland
More informationMelanoma Update: 8th Edition of AJCC Staging System
Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None
More informationGuideline for the Management of Patients Suitable for Immediate Breast Reconstruction
Version History Guideline for the Management of Patients Suitable for Immediate Breast Reconstruction Version Summary of change Date Issued 2.0 Endorsed by the Governance Committee 20.02.08 2.1 Circulated
More informationPATHOLOGY GROUP GUIDELINES FOR THE EXAMINATION AND REPORTING OF COLORECTAL CANCER SPECIMENS
PATHOLOGY GROUP GUIDELINES FOR THE EXAMINATION AND REPORTING OF COLORECTAL CANCER SPECIMENS Produced by: Address: Yorkshire Cancer Network Pathology Group Arthington House, Cookridge Hospital, Hospital
More informationUpdate on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD
Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational and Molecular Pathology
More informationColorectal NSSG. Constitution
Colorectal NSSG Constitution For approvals and version control see Document Management Record on page 10 Ref No: AngCN-SSG-C7 Page 1 of 10 Table of Contents 1 Membership of the Colorectal NSSG (1A-201d)...3
More informationGlenn D. Goldman, MD. Fletcher Allen Health Care. University of Vermont College of Medicine
Glenn D. Goldman, MD Fletcher Allen Health Care University of Vermont College of Medicine Recognize and identify the main types of skin cancer Understand how and why Mohs surgery is utilized for the treatment
More informationMelanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU
Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma
More informationIT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY
IT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY Skin, Bones, and other Private Parts Symposium Dermatology Lectures by Debra Shelby, PhD, DNP, FNP-BC, FADNP, FAANP Debra Shelby,
More informationGuideline for the Management of Vulval Cancer
Version History Guideline for the Management of Vulval Cancer Version Date Brief Summary of Change Issued 2.0 20.02.08 Endorsed by the Governance Committee 2.1 19.11.10 Circulated at NSSG meeting 2.2 13.04.11
More informationKnow who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated
Lindy P. Fox, MD Associate Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco Applies to adults without history of malignancy or premalignant
More informationMichael T. Tetzlaff MD, PhD
Update on American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma Emphasis on concise and accurate reporting of primary and metastatic melanoma for effective risk stratification
More informationINTERNAL VALIDATION REPORT (MULTI-DISCIPLINARY TEAM)
INTERNAL VALIDATION REPORT (MULTI-DISCIPLINARY TEAM) Network Trust MDT NECN N Tees & Hartlepool North Tees And Hartlepool Date Self Assessment Completed 23rd July 2009 Date of IV Review 19th June 2009
More informationJuly 2012 SKIN SURGERY SERVICE BRIEFING NOTES
SKIN SURGERY SERVICE BRIEFING NOTES Introduction The WBoP PHO has an agreement with the BoP District Health Board to deliver the Skin Surgery Service. The current period will expire on 30 June 2012 and
More informationSkin lesions suspicious for melanoma: New Zealand excision margin guidelines in practice
Skin lesions suspicious for melanoma: excision margin guidelines in practice Tess Brian MBBS; 1 Michael B. Jameson MBChB, FRACP, FRCP, PhD 2,3 1 Department of Plastic and Reconstructive Surgery, Waikato
More informationHistopathology: skin pathology
Histopathology: skin pathology These presentations are to help you identify, and to test yourself on identifying, basic histopathological features. They do not contain the additional factual information
More informationQA Processes. Philip DaCosta BSCP QA Lead, Yorkshire & the Humber September 2013
QA Processes Philip DaCosta BSCP QA Lead, Yorkshire & the Humber September 2013 Standards QA visits Dashboards BCSP standards Standards for Organisation Service delivery Reporting Data quality Audit and
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationNPQR Quality Payment Program (QPP) Measures 21_18247_LS.
NPQR Quality Payment Program (QPP) Measures 21_18247_LS MEASURE ID: QPP 99 MEASURE TITLE: Breast Cancer Resection Pathology Reporting pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes)
More informationDermatopathology. Dr. Rafael Botella Estrada. Hospital La Fe de Valencia
Dermatopathology Dr. Rafael Botella Estrada. Hospital La Fe de Valencia Melanoma and mimics Dr. Martin Mihm Malignant lesions result from the accumulation of mutations Class I lesions (benign) Class II
More informationCLINICAL EFFECTIVENESS
Re-audit of gastrointestinal tract specimens with respect to compliance with RCPath guidelines Dr Manisha Ram Dr Moina Kadri Background epidemiology and aetiology Over the past 20 years there has been
More informationGlenn D. Goldman, MD. University of Vermont Medical Center. University of Vermont College of Medicine
Glenn D. Goldman, MD University of Vermont Medical Center University of Vermont College of Medicine Recognize and identify the main types of skin cancer and their precursors Identify and understand new
More informationTracking skin cancers and melanoma at the microscopic level
Tracking skin cancers and melanoma at the microscopic level Rosalie Elenitsas, M.D. Professor of Dermatology Director of Dermatopathology Hospital of the University of Pennsylvania May 12, 2017 Outline
More informationBRITISH ASSOCIATION OF DERMATOLOGISTS WORKING PARTY REPORT ON SETTING STANDARDS FOR MOHS MICROGRAPHIC SURGERY SERVICES
BRITISH ASSOCIATION OF DERMATOLOGISTS WORKING PARTY REPORT ON SETTING STANDARDS FOR MOHS MICROGRAPHIC SURGERY SERVICES Recommendations of the British Society for Dermatological Surgery and British Association
More informationGenetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology
Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing
More informationSubject Index. Dry desquamation, see Skin reactions, radiotherapy
Subject Index Actinic keratosis disseminated disease 42 surgical excision 42 AIDS, see Kaposi s sarcoma Amifostine, skin reaction prophylaxis 111 Basal cell carcinoma, superficial X-ray therapy Bowen s
More informationAttending Physician Statement- Cancer or Carcinoma in-situ
Instruction to doctor: This patient is insured with us against the happening of certain contingent events associated with his health. A claim has been submitted in connection with Cancer or Carcinoma in-situ.
More informationBenign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc
1 Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc Benign lesions Seborrheic Keratoses: Warty, stuck-on Genetics and birthdays Can start in late
More informationأملس عضلي غرن = Leiomyosarcoma. Leiomyosarcoma 1 / 5
Leiomyosarcoma 1 / 5 EPIDEMIOLOGY Exact incidence is unknown, but older studies suggest that leiomyosarcomas comprise approximately 3 percent of soft-tissue sarcomas. Superficial leiomyosarcoma occurs
More informationGuidelines for the Management of Suspected Sarcoma in Primary Care
Guidelines for the Management of Suspected Sarcoma in Primary Care Author: Anglia Cancer Network Sarcoma SSG Document Approved Date: 16-Dec-10 Review Date: December 2012 Ref Code: AngCN-SSG-Sa1 Status:
More informationINTERNAL VALIDATION REPORT...
INTERNAL VALIDATION REPORT... Network Trust Team AngCN CAMBRIDGE UNIVERSITY HOSPITALS Addenbrookes Sarcoma Locality Measures (11-1D-1l) - 2011/12 Date Self Assessment Completed 30th November 2011 Date
More informationSkin Cut Up D R R O K I A H A L I C O N S U L T A N T D E R M A T O P A T H O L O G I S T S T H
Skin Cut Up D R R O K I A H A L I C O N S U L T A N T D E R M A T O P A T H O L O G I S T S T H General Instructions 5.1.1 The type of biopsy is documented. 5.1.2 Orientated or not (suture indicating what
More informationDiagnostics guidance Published: 11 November 2015 nice.org.uk/guidance/dg19
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions Diagnostics guidance Published: 11 November 2015 nice.org.uk/guidance/dg19 NICE 2018. All rights reserved. Subject to Notice of
More informationGreater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy
Greater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy Authors: Dr Gordon Armstrong, Dr Sue Pritchard 1. General Comments 1.1 Cancer reporting: Biopsies
More informationLarge majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest risk.
Basics of Skin Cancer Detection and Treatment of Non- Melanoma Skin Cancers Large majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest
More informationCatholic University of Louvain, St - Luc University Hospital Head and Neck Oncology Programme. Anatomopathology. Pathology 1 Sept.
Anatomopathology Pathology 1 Anatomopathology Biopsies Frozen section Surgical specimen Peculiarities for various tumor site References Pathology 2 Biopsies Minimum data, which should be given by the pathologist
More informationDr. Brent Doolan, BSc MBBS MPH
Impact of partial biopsies on the need for complete excisional surgery in the management of cutaneous melanomas: A multi-centre review Dr. Brent Doolan, BSc MBBS MPH Peter MacCallum Cancer Centre, Melbourne
More informationMelanoma and Dermoscopy. Disclosure Statement: ABCDE's of melanoma. Co-President, Usatine Media
Melanoma and Dermoscopy Richard P. Usatine, MD, FAAFP Professor, Family and Community Medicine Professor, Dermatology and Cutaneous Surgery Medical Director, University Skin Clinic University of Texas
More informationHuman Papillomavirus Testing in Head and Neck Carcinomas
Human Papillomavirus Testing in Head and Neck Carcinomas Guideline from the College of American Pathologists Early Online Release Publication: Archives of Pathology & Laboratory Medicine 12/18/2017 Overview
More information05/07/2018. Organisation. The English screening programme what is happening? Organisation. Bowel cancer screening in the UK is:
Organisation The English screening programme what is happening? Phil Quirke Lead Pathologist Bowel Cancer Screening PHE England Bowel Cancer Screening Pathology Committee Started 2006 with roll out 4 devolved
More informationCommon Benign Lesions and Skin Cancers. 22nd May 2015 Dr Mark Foley
Common Benign Lesions and Skin Cancers 22nd May 2015 Dr Mark Foley Thank you for downloading this file. This intended to supplement the presentation given at the NZ Wound Care Conference, it is not intended
More informationDr Rosalie Stephens. Mr Richard Martin. Medical Oncologist Auckland City Hospital Auckland
Dr Rosalie Stephens Medical Oncologist Auckland City Hospital Auckland Mr Richard Martin General Surgeon Melanoma Unit Team Waitemata District Health Board Auckland 8:30-9:25 WS #99: Interactive Case Studies
More informationSection 1: Personal information
A survey on the use of ultrasound examination of the regional lymph nodes in the follow up of patients with high-risk cutaneous squamous cells carcinomas (SCCs). Note: In the definition of cutaneous squamous
More informationNonmelanoma skin cancers
Skin cancer Philip Clarke Nonmelanoma skin cancers Treatment options Background Australia has one of the highest skin cancer rates in the world. Early detection and treatment of skin cancer is vital to
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationI have a skin lump doc! What s next? 12 th August 2017 Dr. Sue-Ann Ho Ju Ee
I have a skin lump doc! What s next? 12 th August 2017 Dr. Sue-Ann Ho Ju Ee Some thoughts Is this skin cancer? How common is this? How likely is this in this patient? What happens next if it s something
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationLiving Beyond Cancer Skin Cancer Detection and Prevention
Living Beyond Cancer Skin Cancer Detection and Prevention Cutaneous Skin Cancers Identification Diagnosis Treatment options Prevention What is the most common cancer in people? What is the most common
More informationClinical characteristics
Skin Cancer Fernando Vega, MD Seattle Healing Arts Clinical characteristics Precancerous lesions Common skin cancers ACTINIC KERATOSIS Precancerous skin lesions Actinic keratoses Dysplastic melanocytic
More informationShared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Lung /chest wall sarcomas incl. pulmonary metastatectomy Version 2
Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Lung /chest wall sarcomas incl. pulmonary metastatectomy Version 2 Background Sarcomas that arise in the lung de novo are
More informationAudit of plastic surgeons understanding of pathology reports of skin neoplasia
The British Association of Plastic Surgeons (2004) 57, 134 138 Audit of plastic surgeons understanding of pathology reports of skin neoplasia Y.S. Lau a, S.K. Suvarna b, *, L. Kangesu a, A. Mosahebi a
More informationNational Cancer Peer Review Programme
National Cancer Peer Review Programme Julia Hill Acting Deputy National Co-ordinator What is Cancer Peer Review? A quality assurance process for cancer services. An integral part of Improving Outcomes
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationSkin cancer excision performance in Scottish primary and secondary care:
Research Wei Yann Haw, Pariyawan Rakvit, Susannah J Fraser, Andrew G Affleck and S Alexander Holme Skin cancer excision performance in Scottish primary and secondary care: a retrospective analysis Abstract
More informationUpdate on Cutaneous Mesenchymal Tumors. Thomas Brenn
Update on Cutaneous Mesenchymal Tumors Thomas Brenn Cutaneous Mesenchymal Tumours Wide morphological and biological spectrum Myofibroblastic, smooth muscle, neural, vascular, apidocytic, undifferentiated;
More informationMalignant tumors of melanocytes: Part 1. Deba P Sarma, MD., Omaha
Malignant tumors of melanocytes: Part 1 Deba P Sarma, MD., Omaha The melanocytic tumor is one of the most difficult and confusing areas in Dematopathology. It is true that most (95%) of such lesions are
More informationMECHANISMS OF HUMAN DISEASE: LABORATORY SESSION PATHOLOGY OF THE SKIN LAB. Friday, February 12, :30 am 11:00 am
MECHANISMS OF HUMAN DISEASE: LABORATORY SESSION PATHOLOGY OF THE SKIN LAB Friday, February 12, 2012 9:30 am 11:00 am FACULTY COPY GOALS: Describe the basic clinical and morphologic features of various
More informationRE-AUDIT OF THYROID FNA USING THE THY GRADING SYSTEM AND HISTOLOGY AT SUNDERLAND ROYAL HOSPITAL, 2011
Audit: RE-AUDIT OF THYROID FNA USING THE THY GRADING SYSTEM AND HISTOLOGY AT SUNDERLAND ROYAL HOSPITAL, 2011 Auditors: Dr Lena Wilkinson SpR Histopathology Dr. Debra Milne Consultant Histocytopathologist
More information